Insider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells 97,483 Shares of Stock

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) insider Stephen F. Betz sold 97,483 shares of the business's stock in a transaction on Thursday, June 12th. The stock was sold at an average price of $32.23, for a total value of $3,141,877.09. Following the sale, the insider now directly owns 99,713 shares in the company, valued at $3,213,749.99. This trade represents a 49.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Crinetics Pharmaceuticals Stock Down 1.8%

Shares of Crinetics Pharmaceuticals stock traded down $0.57 during midday trading on Monday, hitting $31.20. The company's stock had a trading volume of 533,605 shares, compared to its average volume of 846,075. The stock has a 50-day simple moving average of $31.12 and a 200-day simple moving average of $37.79. The firm has a market capitalization of $2.92 billion, a P/E ratio of -8.36 and a beta of 0.28. Crinetics Pharmaceuticals, Inc. has a 1-year low of $24.10 and a 1-year high of $62.53.

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.05). The firm had revenue of $0.36 million during the quarter, compared to the consensus estimate of $0.10 million. Crinetics Pharmaceuticals's revenue for the quarter was down 43.6% compared to the same quarter last year. During the same quarter last year, the company earned ($0.93) EPS. As a group, sell-side analysts predict that Crinetics Pharmaceuticals, Inc. will post -3.73 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Stifel Nicolaus started coverage on Crinetics Pharmaceuticals in a research note on Tuesday, March 25th. They issued a "buy" rating and a $60.00 price target on the stock. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $74.56.

Institutional Investors Weigh In On Crinetics Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Rhumbline Advisers raised its holdings in shares of Crinetics Pharmaceuticals by 14.1% during the fourth quarter. Rhumbline Advisers now owns 124,078 shares of the company's stock worth $6,344,000 after acquiring an additional 15,359 shares in the last quarter. State of New Jersey Common Pension Fund D raised its stake in shares of Crinetics Pharmaceuticals by 1.9% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 38,049 shares of the company's stock worth $1,945,000 after purchasing an additional 708 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in shares of Crinetics Pharmaceuticals by 4.4% during the 4th quarter. Principal Financial Group Inc. now owns 81,156 shares of the company's stock valued at $4,150,000 after buying an additional 3,447 shares during the last quarter. Venturi Wealth Management LLC bought a new position in Crinetics Pharmaceuticals during the fourth quarter valued at approximately $41,000. Finally, New York State Common Retirement Fund raised its position in Crinetics Pharmaceuticals by 5.2% during the fourth quarter. New York State Common Retirement Fund now owns 155,426 shares of the company's stock valued at $7,947,000 after acquiring an additional 7,735 shares in the last quarter. Institutional investors and hedge funds own 98.51% of the company's stock.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.